Incyte (INCY)
(Delayed Data from NSDQ)
$57.45 USD
-0.75 (-1.29%)
Updated May 23, 2024 04:00 PM ET
After-Market: $57.46 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INCY 57.45 -0.75(-1.29%)
Will INCY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INCY
Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week
Company News For May 14, 2024
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Other News for INCY
Incyte a new hold at Deutsche Bank as key drugs approach patent cliffs
9 Analysts Have This To Say About Incyte
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Incyte (INCY)
Incyte initiated with neutral view at Deutsche Bank, here's why
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings